A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men

Overview of attention for article published in Frontiers in Pharmacology, January 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 11 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 7 publications that cite this research output.

7

The most recent citing publications are shown below. View all 7 publications that cite this research output on Dimensions.

Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial

Article in The Lancet Rheumatology (January 2024)

A phase I study comparing the pharmacokinetics and safety of HS628 (tocilizumab biosimilar) and reference tocilizumab in healthy male subjects

Article in Clinical and Translational Science (July 2023)

Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study

Article in Expert Opinion on Investigational Drugs (May 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.